BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announces that its contract manufacturer

Merit Medical Systems, Inc. announced that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023.

MolecuLight Inc. is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

Caris Life Sciences® announced that the Icahn School of Medicine at Mount Sinai, in New York, NY, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

LIfT BioSciences, (‘LifT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs).

Tonix Pharmaceuticals Holding Corp. today announced comments relating to two recent meetings sponsored by the National Academies of Sciences, Engineering, and Medicine (National Academies) in Washington, D.C. and virtually, relating to the definition of Long COVID and to features of Long COVID that overlap with previously recognized infection-associated chronic conditions.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has purchased the Blink ® product line of eye and contact lens drops from Johnson & Johnson Vision.

Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the approval of its first Clinical Trial Application (CTA) by the Paul-Ehrlich-Institut (PEI) in Germany for KYV101, a novel therapy for the treatment of lupus nephritis (LN).

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

ViaDerma, Inc. is very pleased to announce several exciting business updates for current and prospective shareholders, partners, and healthcare providers.